Zavicefta Dosing Guide1
*To be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process.
†To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process.
‡The total duration shown may include intravenous ZAVICEFTA followed by appropriate oral therapy.
§There is very limited experience with the use of ZAVICEFTA for more than 14 days.
No dosage adjustment is required in:
- The elderly
- Patients with mild renal impairment (estimated CrCl from 51 to ≤80 mL/min)
- Patients with hepatic impairment
The following dose adjustments are recommended in patients with estimated CrCl ≤50 mL/min:
*CrCl estimated using the Cockcroft–Gault formula.
†Dose recommendations are based on PK modelling.
‡ Following each haemodialysis, the recommended dose of ZAVICEFTA should be repeated and continued every 48 hours until next haemodialysis.
cIAI, complicated intra-abdominal infection; CrCl, creatinine clearance; cUTI, complicated urinary tract infection; ESRD, end stage renal disease;
HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia.
1. Zavicefta, Summary of Product Characteristics
Meronem IV 1g – SPC
Legal Category: POM. Basic NHS Cost: 10 vial pack £206.28
Meronem IV 500mg – SPC
Legal Category: POM. Basic NHS Cost: 10 vial pack £103.14